• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Mast Therapeutics announces Phase 2 study of AIR001by the Heart Failure Clinical Research Network

Mast Therapeutics has announced that the Duke Clinical Research Institute will serve as the coordinating center for the Heart Failure Clinical Research Network (HFN) as it conducts a Phase 2 study of AIR001 sodium nitrite inhalation solution. Earlier this year, Mast reported positive results from a Phase 2a AIR001 for the treatment of heart failure that was conducted at the Mayo Clinic.

The randomized, double-blind, placebo-controlled Phase 2 clinical study, called Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF (INDIE-HFpEF), is expected to enroll 100 patients with heart failure with preserved ejection fraction (HFpEF). In addition to AIR001, Mast will provide nebulizers and “regulatory, technical and additional financial support” to the HFN, which is funded by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH).

Mast CEO Brian M. Culley commented, “We appreciate the NIH’s, NHLBI’s, and HFN’s recognition of the study of AIR001 in heart failure as an appropriate area of investigation. This study will accelerate efforts to define the potential efficacy of AIR001 for patients who have heart failure with preserved ejection fraction. This is an area of significant unmet need. There are more than 1 million heart failure hospitalizations each year in the US, about half are patients with HFpEF, and, currently, there are no proven effective therapeutic agents available for this large patient population.”

Read the Mast Therapeutics press release.

Share

published on April 13, 2016

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Proveris_180x150a
    © 2025 OINDPnews